Skip to content
ClinCalc Pro
Menu
Heart Failure

Patiromer

Brand names: Veltassa

Used in: Hyperkalaemia

Patiromer is an orally administered non-absorbed potassium-binding polymer used to treat hyperkalaemia, including in patients with heart failure or chronic kidney disease taking renin-angiotensin-aldosterone system inhibitors.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It exchanges calcium for potassium in the lumen of the gastrointestinal tract, predominantly the colon, increasing faecal potassium excretion and thereby lowering serum potassium.

Prescribing in practice

  • Separate patiromer from other oral medicines by several hours because it can bind co-administered drugs in the gut and reduce their absorption.
  • It is not for emergency treatment of life-threatening hyperkalaemia owing to its delayed onset of action.
  • It can lower serum magnesium and cause gastrointestinal effects such as constipation; review concomitant potassium-raising therapy and dietary potassium.

Monitoring

Monitor serum potassium and magnesium during treatment and after any dose adjustment, with more frequent checks when renin-angiotensin therapy is changed.

Counselling the patient

  • Take other medicines separated from this one by a few hours as advised.
  • Do not heat the medicine and mix the powder with water as instructed before taking.
  • Continue with any prescribed low-potassium diet and report constipation.

Evidence & guidelines

Trials including OPAL-HK and AMETHYST-DN showed patiromer lowers and maintains normal serum potassium and can enable continued renin-angiotensin-aldosterone inhibition; it is recommended by NICE in specified hyperkalaemia settings.

Reference: DIAMOND trial NEJM 2019; 380(18):1717-1728; NICE TA592; MHRA 2017; ESC HF Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.